

Michael C Lowe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9504950/publications.pdf>

Version: 2024-02-01

54
papers

478
citations

759233

12
h-index

794594

19
g-index

56
all docs

56
docs citations

56
times ranked

596
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience. Journal of the American College of Surgeons, 2019, 228, 644-649.	0.5	65
2	Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-II). Cancer, 2021, 127, 2251-2261.	4.1	37
3	Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. Annals of Surgical Oncology, 2019, 26, 2486-2494.	1.5	35
4	Important Prognostic Factors in Adenocarcinoma of the Ampulla of Vater. American Surgeon, 2009, 75, 754-761.	0.8	29
5	FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).. Journal of Clinical Oncology, 2022, 40, 9510-9510.	1.6	22
6	Neoadjuvant therapy of locally/regionally advanced melanoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986695.	3.2	21
7	Morbidity and Outcomes Following Axillary Lymphadenectomy for Melanoma: Weighing the Risk of Surgery in the Era of MSLT-II. Annals of Surgical Oncology, 2018, 25, 465-470.	1.5	19
8	Important prognostic factors in adenocarcinoma of the ampulla of Vater. American Surgeon, 2009, 75, 754-60; discussion 761.	0.8	19
9	Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. Annals of Surgical Oncology, 2022, 29, 791-801.	1.5	18
10	The evolving landscape of immunotherapy in solid tumors. Journal of Surgical Oncology, 2021, 123, 798-806.	1.7	17
11	Increased homeostatic cytokines and stability of HIV-infected memory CD4 T-cells identify individuals with suboptimal CD4 T-cell recovery on-ART. PLoS Pathogens, 2021, 17, e1009825.	4.7	17
12	<i>The Impact of Shave Biopsy on The Management of Patients with Thin Melanomas</i>. American Surgeon, 2011, 77, 1050-1053.	0.8	16
13	Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. Journal of the American College of Surgeons, 2021, 232, 424-431.	0.5	14
14	Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC).. Journal of Clinical Oncology, 2018, 36, 9543-9543.	1.6	14
15	FcγRIIB is a T cell checkpoint in antitumor immunity. JCI Insight, 2021, 6, .	5.0	13
16	The impact of shave biopsy on the management of patients with thin melanomas. American Surgeon, 2011, 77, 1050-3.	0.8	11
17	International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. Annals of Surgical Oncology, 2020, 27, 1420-1429.	1.5	10
18	Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. European Journal of Surgical Oncology, 2020, 46, 2140-2146.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. <i>Annals of Surgical Oncology</i> , 2020, 27, 5107-5118.	1.5	8
20	Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6995-7003.	1.5	8
21	Triple therapy with intralesional 5-fluorouracil, chemowraps, and acitretin: A well-tolerated option for treatment of widespread cutaneous squamous cell carcinomas on the legs. <i>JAAD Case Reports</i> , 2019, 5, 1051-1054.	0.8	7
22	Neoadjuvant Treatments for Advanced Resectable Melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 216-221.	1.7	7
23	Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma: An updated analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21015-e21015.	1.6	7
24	Association of proton pump inhibitors with survival in Veterans with non-small cell lung cancer receiving immunotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18729-e18729.	1.6	6
25	Management of intussusception in patients with melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 897-902.	1.7	5
26	The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 5259-5266.	1.5	5
27	The Impact of Obesity on Surgically Treated Locoregional Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6140-6151.	1.5	5
28	Surgical Considerations and Systemic Therapy of Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 141-159.	1.5	4
29	Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II). <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	4
30	Association of concomitant NSAID and immunotherapy on outcomes in patients with non-small cell lung cancer: Analysis of the National Veterans Health Administration Database.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9107-9107.	1.6	3
31	ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience. <i>Annals of Surgical Oncology</i> , 2021, 29, 804.	1.5	3
32	A Phase III, Multicenter, Randomized Controlled Trial Investigating 1-cm Versus 2-cm Surgical Excision Margins for Stage II Primary Cutaneous Melanoma (MelMarT-II). <i>Annals of Surgical Oncology</i> , 2022, 29, 4050-4051.	1.5	3
33	A Call to Arms: Surgeons Must Play an Important and Early Role in the Management of Patients with Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 4180-4181.	1.5	2
34	Neoadjuvant Therapy for Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 445-453.	1.5	2
35	Effect of antibiotic therapy on immunotherapy outcomes for non-small cell lung cancer: Analysis from the Veterans Health Administration Database.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9017-9017.	1.6	2
36	S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS9585-TPS9585.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable metastatic melanoma.. Journal of Clinical Oncology, 2019, 37, TPS9603-TPS9603.	1.6	2
38	Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.. Journal of Clinical Oncology, 2020, 38, 10061-10061.	1.6	2
39	MERLIN_001: A prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of patients with SN-negative melanoma.. Journal of Clinical Oncology, 2022, 40, TPS9606-TPS9606.	1.6	2
40	Recurrence Patterns after Primary Excision of Invasive Melanoma with Melanoma in situ at the Margin. American Surgeon, 2018, 84, 1319-1325.	0.8	1
41	ASO Author Reflections: Cutaneous Melanoma as Model System for the Obesity Paradox in Cancer. Annals of Surgical Oncology, 2021, 28, 6152-6153.	1.5	1
42	S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.. Journal of Clinical Oncology, 2020, 38, TPS10090-TPS10090.	1.6	1
43	Ford Versus Ferrari: Novel Technologies in the Setting of a Reliable Standard. Annals of Surgical Oncology, 2021, 29, 758.	1.5	1
44	Revisiting the Strait of Messina: The Balance Between Optimal Oncologic Outcomes and Complications From Surgery. Annals of Surgical Oncology, 2017, 24, 302-304.	1.5	0
45	ASO Author Reflections: Optimizing the Outcomes for Patients: The Evolution of the Management of Regional Disease in Patients with Melanoma. Annals of Surgical Oncology, 2018, 25, 908-909.	1.5	0
46	Reducing injury response to surgery with repurposed drugs: An evolving approach to prevention of cancer metastases. Cancer, 2020, 126, 3916-3918.	4.1	0
47	Winship 4851-19: A pilot study of neoadjuvant and adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma.. Journal of Clinical Oncology, 2021, 39, TPS9593-TPS9593.	1.6	0
48	Isolated same-basin lymph node recurrence after precision lymph node excision for clinically evident melanoma metastasis.. Journal of Clinical Oncology, 2021, 39, 9576-9576.	1.6	0
49	Association of azole antifungals with survival in patients with non-small cell lung cancer receiving immunotherapy.. Journal of Clinical Oncology, 2021, 39, e18777-e18777.	1.6	0
50	In Search of a More Accurate Nodal Staging System for Melanoma. JAMA Surgery, 2021, 156, e214306.	4.3	0
51	The (R)evolution of Melanoma Care. Surgical Oncology Clinics of North America, 2020, 29, xv-xvi.	1.5	0
52	Management of Melanoma Patients with Positive Nodes. Advances in Surgery, 2020, 54, 191-204.	1.3	0
53	ASO Visual Abstract: Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in MSLT-II. Annals of Surgical Oncology, 2022, , 1.	1.5	0
54	Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis. Journal of the American Academy of Dermatology, 2022, , .	1.2	0